After examining study data from pediatric patients with both psoriasis and psoriatic arthritis (PsA), the FDA approved ustekinumab as a treatment for patients aged 6–17 years old with PsA.
Psoriatic Arthritis & the Obese Patient
Estimates from the National Psoriasis Foundation indicate that more than 8 million people in the U.S. suffer from psoriasis and that approximately 30% of those individuals develop psoriatic arthritis (PsA).1 Given these statistics, roughly 2.4 million people in the country are likely affected by PsA. Moreover, patients with this systemic condition carry a higher-than-average burden…
Updates on PsA: Insights into the Latest Psoriatic Arthritis Treatments & Research
Ana-Maria Orbai, MD, MHS, addressed the latest research into psoriatic arthritis (PsA), including a comprehensive overview of the latest FDA-approved treatments and their implications for clinical practice.
Phase 2 Study Shows Promising Results for Deucravacitinib in PsA
Research has demonstrated that deucravacitinib is significantly more efficacious than placebo for achieving minimal disease activity in patients with active PsA after 16 weeks of treatment.
Spine School: Axial Manifestations of Psoriatic Arthritis
This EULAR 2022 session emphasized the importance of recognizing the axial manifestations of psoriatic arthritis and treating these symptoms accordingly.
PsA Trial Design Can Improve Patient Safety, Outcomes
For best safety and efficacy outcomes, trials in psoriatic arthritis should use active comparators and stricter remission criteria, with outcome measures that are important to patients.
European Medicines Agency Committee Issues Positive Opinion for Secukinumab in Pediatric Arthritic Disease
In the E.U., secukinumab is edging closer to approval for use in pediatric patients with juvenile idiopathic arthritis (JIA), specifically those with enthesitis-related arthritis (ERA) and juvenile psoriatic arthritis (PsA). In May, the Committee for Medicinal Products for Human Use of the European Medicines Agency issued a positive opinion on expanding its indications.
Data Accumulate to Suggest HLA-B27 Status May Drive Axial Phenotype in SpA
HLA-B27 may be a phenotypic expression of axial spondyloarthritis (SpA), according to a large international study. The study found patients with axial SpA who were positive for HLA-B27 had more severe radiographic damage than those who were negative for HLA-B27, and three quarters of study patients with ankylosis spondyloarthritis were HLA-B27 positive.
Medication Preferences & Current Practices for PsA
With many new agents designed to treat PsA, rheumatologists and patients have options. Schwartzman et al. examined the real-world use of different treatments and ranked patient medication preferences.
Imaging of Axial Psoriatic Arthritis
The axial phenotype of psoriatic arthritis (axPsA) is an excellent example of a major controversy in rheumatology that has become the focus of attention because of the emergence of new therapies with different mechanisms of action for alleviating joint inflammation. It was first described in 1961 but, until recently, it has largely remained under the…
- « Previous Page
- 1
- …
- 3
- 4
- 5
- 6
- 7
- …
- 16
- Next Page »